It is very uncertain whether clazakizumab changes clinical improvement D28b compared with standard care/placebo (very low certainty).
It is very uncertain whether clazakizumab changes clinical improvement D60 or more compared with standard care/placebo (very low certainty).
It is very uncertain whether clazakizumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether clazakizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether clazakizumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
Clazakizumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).